Viking Therapeutics Shares Rise on Positive Obesity Drug Trial Results
Viking Therapeutics (VKTX) experienced a significant stock increase of over 25% following the release of trial data for its weight loss therapy, VK2735. The results showed a favorable safety profile according to Wall Street analysts. The drug is being tested in Phase II trials under the identifier VK2735-102 and has drawn attention due to growing demand for effective obesity treatments. Analysts are optimistic about its potential market impact given current trends in metabolic health therapies. Investor sentiment appears positive, with shares reaching their highest intraday gain since February 2024.
Tickers: $VKTX
Topics: biotech stock_movement weight_loss_therapy